Novozymes
Albumedix technology extends dosing interval in Behring haemophilia B drug
March 22, 2016Manufacturing and Production, Research and Development Albumedix, GSK, Idelvion, Novozymes, VELTIS, haemophilia B
Novozymes subsidiary Albumedix has scored another big pharma tie-up for its albumin-based half-life extension technology VELTIS, which this time is …
Pharma manufacturing news in brief
February 4, 2013Manufacturing and Production ACS, Amcor, Beanne, Iogen Bio-products, Novozymes, Pluristem
Facility investments from Amcor and Pluristem, Beanne Chemical falls foul of FDA inspectors, Novozymes acquisition plus a green chemistry app.
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
